Barclays PLC Has $174,000 Position in Sanara MedTech Inc. (NASDAQ:SMTI)

Barclays PLC raised its position in shares of Sanara MedTech Inc. (NASDAQ:SMTI) by 323.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,731 shares of the company’s stock after purchasing an additional 4,376 shares during the quarter. Barclays PLC owned 0.07% of Sanara MedTech worth $174,000 at the end of the most recent quarter.

Separately, Geode Capital Management LLC raised its stake in Sanara MedTech by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock valued at $2,670,000 after purchasing an additional 3,755 shares during the period. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Trading Up 10.9 %

NASDAQ SMTI opened at $37.72 on Thursday. Sanara MedTech Inc. has a 1-year low of $26.00 and a 1-year high of $40.75. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $329.67 million, a PE ratio of -38.10 and a beta of 1.55. The firm’s fifty day simple moving average is $34.65 and its 200-day simple moving average is $32.80.

Sanara MedTech (NASDAQ:SMTI) last posted its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.28. The firm had revenue of $21.67 million for the quarter. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. During the same period in the previous year, the company earned ($0.13) earnings per share. As a group, sell-side analysts anticipate that Sanara MedTech Inc. will post -1.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SMTI. Cantor Fitzgerald reissued an “overweight” rating and set a $44.00 target price on shares of Sanara MedTech in a research note on Wednesday. HC Wainwright started coverage on shares of Sanara MedTech in a research note on Monday, December 23rd. They issued a “buy” rating and a $50.00 price target on the stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.